A Phase 2 interventional study of TS-091 5mg and TS-091 10mg in Narcolepsy, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 16 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Narcolepsy with a site in Japan — 5 open to participants now, 5 under way, 2 of them phase 3. Narcolepsy · Japan.
Among the 13 studies in Narcolepsy with a site in Japan, this one is the 12th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 1st registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →5 of the 13 studies in Narcolepsy with a site in Japan are open now. Recruiting first, the newest first:
Takeda · Sites in Japan, United States, Australia and 4 more countries
Ages 18–70
Alkermes, Inc. · Sites in Japan, United States, Australia and 12 more countries
Ages 18–70
Eisai Inc. · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
Takeda · Sites in Japan, United States, China and 4 more countries
Ages 18–70
Takeda · Sites in Japan, United States, Australia and 9 more countries
Ages 16–70
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 16 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 3
First in 2017; this study’s year is marked. 2 started in 2017.
This study's enrollment of 53 is below the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 88 across the 13 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 4 most frequent:
Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.
Taisho Pharmaceutical Co., Ltd. has 1 study filed under Narcolepsy — fewer than ten, so there is no comparison to draw.
4 of the studies in Narcolepsy with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT06952699TakedaA Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | 2026-11-30 |
| NCT07493265Eisai Inc.A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | 2027-02-14 |
| NCT07633301TakedaA Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | 2027-11-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Narcolepsy with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety after administration of TS-091 compared with placebo in patients with narcolepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TS-091 5mg
Drug: TS-091 10mg
Drug: Placebo
Orally taken once daily for 3 weeks
Orally taken once daily for 3 weeks
Orally taken once daily for 3 weeks
Mean sleep latency in maintenance of wakefulness test
Time frame: 3 weeks
Total score on the epworth sleepiness scale
Time frame: 3 weeks
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2018, 13 months.
Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 13 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taisho Pharmaceutical Co., Ltd. →